To address the biological significance of ZEB1 in lung cancer stem cells resistant to osimertinib in this clinical setting, further studies to establish osimertinib‐resistant persisters from EGFR‐mutant NSCLC cells are necessary. Here, EGFR is linked to non-small cell lung carcinoma.